Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Wang

Showing results (411-420 of 603) with videos related to

Pageof 61
Sort By:
British Journal of Haematology|August 26, 2010
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphomaJorge E Romaguera, Luis E Fayad, Peter McLaughlin, et al.
Blood|July 25, 2009
Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivoZurina Romay-Penabad, Maria Guadalupe Montiel-Manzano, Tuya Shilagard, et al.
World Neurosurgery|February 21, 2013
Assessment of quality of life after surgery for spinal metastases: position statement of the Global Spine Tumour Study GroupDavid Choi, Steven Morris, Alan Crockard, et al.
Acta Neuropathologica|November 19, 2013
Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymomaLindsey M Hoffman, Andrew M Donson, Ichiro Nakachi, et al.
Pediatric Blood & Cancer|October 14, 2014
Humanism and professionalism education for pediatric hematology-oncology fellows: A model for pediatric subspecialty trainingJennifer C Kesselheim, Mark Atlas, Denise Adams, et al.
European Urology|July 28, 2023
Does Urologist-level Utilization of Active Surveillance for Low-risk Prostate Cancer Correspond with Utilization of Active Surveillance for Small Renal Masses?Michael Wang, Sophie Wittenberg, Michael L Cher, et al.
Blood|June 13, 2014
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsPaul G Richardson, Rachid Baz, Michael Wang, et al.
Journal of Hematology & Oncology|October 31, 2021
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO studyMichael Wang, Radhakrishnan Ramchandren, Robert Chen, et al.
Nano Letters|February 21, 2018
Three-dimensional Architecture Enabled by Strained Two-dimensional Material HeterojunctionShuai Lou, Yin Liu, Fuyi Yang, et al.
Oncotarget|December 17, 2014
Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380Xiao Huang, Mengru Cao, Li Wang, et al.
Pageof 61

Showing results (411-420 of 603) with videos related to

Sort By:
Pageof 61
British Journal of Haematology|August 26, 2010
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphomaJorge E Romaguera, Luis E Fayad, Peter McLaughlin, et al.
Blood|July 25, 2009
Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivoZurina Romay-Penabad, Maria Guadalupe Montiel-Manzano, Tuya Shilagard, et al.
World Neurosurgery|February 21, 2013
Assessment of quality of life after surgery for spinal metastases: position statement of the Global Spine Tumour Study GroupDavid Choi, Steven Morris, Alan Crockard, et al.
Acta Neuropathologica|November 19, 2013
Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymomaLindsey M Hoffman, Andrew M Donson, Ichiro Nakachi, et al.
Pediatric Blood & Cancer|October 14, 2014
Humanism and professionalism education for pediatric hematology-oncology fellows: A model for pediatric subspecialty trainingJennifer C Kesselheim, Mark Atlas, Denise Adams, et al.
European Urology|July 28, 2023
Does Urologist-level Utilization of Active Surveillance for Low-risk Prostate Cancer Correspond with Utilization of Active Surveillance for Small Renal Masses?Michael Wang, Sophie Wittenberg, Michael L Cher, et al.
Blood|June 13, 2014
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsPaul G Richardson, Rachid Baz, Michael Wang, et al.
Journal of Hematology & Oncology|October 31, 2021
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO studyMichael Wang, Radhakrishnan Ramchandren, Robert Chen, et al.
Nano Letters|February 21, 2018
Three-dimensional Architecture Enabled by Strained Two-dimensional Material HeterojunctionShuai Lou, Yin Liu, Fuyi Yang, et al.
Oncotarget|December 17, 2014
Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380Xiao Huang, Mengru Cao, Li Wang, et al.
Pageof 61